The study of patients with TNBC who carry the BRCA-1 and BRCA-2 mutation is one analysis pathway, as these tumours are sensitive to PARP (polyadenosine diphosphate ribose polymerase 1) inhibitors like Olaparib, which penetrates the BBB [15, 44]. Here, BRCA1 is linked to neoplasm.